RHOA and intrahepatic cholangiocarcinoma: Here, in addition to inhibiting active RhoA and YAP1 transcriptional activity known in previous studies, simvastatin or verteporfin treatment also further reduced the mRNA and protein levels of ANLN in ICC, subsequently destroying the stability of the ANLN/RhoA/YAP1/TEAD1 feed-forward loop.